Continuum of Care in Pain Management: Bridging the Gap (Part 4 of 4) Case 4: Patient With Knee Osteoarthritis Pain
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, October 3, 2012
Note: Credit Is No Longer Available
 | Steven P. Stanos, DO Executive Medical Director, Rehabilitation and Performance Medicine Swedish Pain Services Swedish Health System Seattle, WA |
Dr. Scott Fischman of the University of California, Davis, explains, "There's no way that pain specialists will be able to manage even a sizeable fraction of the pain that's out there in America." Physicians in both primary and non-pain specialty care will increasingly need to manage pain. Dr. Perry Fine of the University of Utah states, "All healthcare professionals must understand [] the treatments used to provide [pain] relief and the barriers that prevent good management."
With the increasing prevalence of osteoarthritis (OA) in the United States,(1) all prescribing clinicians must capably manage pain care. However, while guidelines for diagnosis and nonpharmacological and pharmacological therapies exist for pain care, no uniform knowledge set exists among providers. Evidence- and outcomes-based practice is lacking, often resulting in delayed services for pain and poorer outcomes.(2)
This neuroscienceCME Medical Simulation presents a complex patient with new knee pain in a case addressing diagnosis, biomarker research progress, and multimodal management. To address clinicians' and patients' concerns, the case further illustrates indications and contraindications for opioid use in chronic pain.
- Holt HL, Katz JN, Reichmann WM, et al. Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults. Osteoarthritis Cartilage. 2011;19(1):44-50. PMID: 20955807.
- McHugh GA, Luker KA, Campbell M, Kay PR, Silman AJ. A longitudinal study exploring pain control, treatment and service provision for individuals with end-stage lower limb osteoarthritis. Rheumatology (Oxford). 2007;46(4):631-637. PMID: 17043045.
Address gaps in the diagnosis and multimodal management of chronic osteoarthritis pain.
At the end of this CE activity, participants should be able to:
- Name elements of the EULAR diagnostic guidelines and improve clinical rationales for ordering imaging studies in the diagnosis of osteoarthritis (OA).
- Effectively stage guideline-recommended multimodal therapies, considering relative contraindications, and then combine these abilities to deliver effective pain management.
- Stage opioid medications among analgesic agents (in terms of efficacy, safety, and contraindications); identify which subgroups of patients are more likely than others to have opioid control concerns; and apply the "universal precautions" approach for opioid use.
Supported in part by an educational grant from Endo Pharmaceuticals.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Supported in part by Purdue Pharma L.P.
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in pain or osteoarthritis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-11-018-H01-P (recorded programs)
Activity Type: application-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure of Relevant Financial Relationships with Commercial Interests
CME Outfitters, LLC, adheres to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Dr. Stanos has disclosed that he receives grants from Pfizer Inc. He serves as a consultant to, or is on the advisory boards of, Covidien; Eli Lilly and Company; Endo Pharmaceuticals; Grünenthal; King Pharmaceuticals, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Purdue Pharma L.P. He is on the speakers bureaus of Eli Lilly and Company; Endo Pharmaceuticals; Forest Laboratories, Inc.; King Pharmaceuticals, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Pfizer Inc.
Disclosures were obtained from the planning committee members and are on file with CME Outfitters Health Office of Continuing Professional Development (OCPD) for review.
Ruth Cody, BSN, RN-BC (Content/Peer Reviewer) has no disclosures to report.
Howard Bliwise, MD (Content/Peer Reviewer) has no disclosures to report.
Nancy Jennings, MSN, MBA, MHA, RNC (Content/Peer Reviewer) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Joy B. Leffler, MLA, NASW (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Endo Pharmaceuticals, Lilly USA, LLC, and Purdue Pharma L.P. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PL-028-100311-90
